The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma

This study compares two treatment approaches for people with intermediate-stage recurring liver cancer (hepatocellular carcinoma that has come back after initial treatment). One group gets a combination of TACE (a procedure to block blood supply to the tumor) plus the targeted drug lenvatinib. The other group gets the same combination plus tumor ablation (a procedure that destroys tumor tissue using heat or cold). Researchers want to find out which approach controls the cancer better. **You may be eligible if...** - You are between 18 and 75 years old - Your liver cancer has returned (recurrent HCC) and is at an intermediate stage (2–3 lesions, at least one over 3 cm, no more than 6 tumors total, each under 5 cm) - There is no spread outside the liver and no major blood vessel involvement - Your liver is still functioning reasonably well (Child-Pugh A or B) - You showed no progression after your first TACE treatment **You may NOT be eligible if...** - Your cancer has spread outside the liver - You have primary (not recurrent) liver cancer - You have more than 6 tumors or a tumor larger than 5 cm Talk to your doctor to see if this trial is right for you.